中国生物科技服务(08037.HK)构建BNCT“药-械-医”全闭环 产业模式全面升级

智通财经
Aug 12
【中国生物科技服务(08037.HK)构建BNCT“药-械-医”全闭环 产业模式全面升级】智通财经APP获悉,2026年8月12日,中国生物科技服务控股有限公司(08037.HK)与日本Stella Pharma(东证:4888)正式签署合作协议。根据协议,Stella Pharma将向中国生物科技服务授予Steboronine®硼药在中国内地的独家商业化权益,包括开发许可、代理及总进口代理/分销权。早在2025年5月8日公司就与SP签订,拟通过进一步授权合作,将硼药生产国产化,并转让制剂生产技术。这次的合作进一步夯实了中国生物科技在该领域的上游产业布局。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10